← All trials
NCT04407377
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2020
- Primary completion
- Sep 30, 2020
- Completion date
- Dec 31, 2020
- First posted
- May 29, 2020
- Last posted
- May 29, 2020
- Enrollment
- 36
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Neurana Pharmaceuticals, Inc.Lead sponsor
- Neurana Pharmaceuticals, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.